Waxman says that Congress has not given up on biosimilar legislation

WASHINGTON The idea of biosimilar legislation has not yet been given up by supporters, even though it was not included in the Food and Drug Administration Amendments Act, which Congress recently passed.

“The issue is squarely on the table,” Rep. Henry Waxman, D-Calif., said Sept. 24 at Scherago International’s Biosimilars 2007 conference.  Waxman reiterated his belief that follow-on biologics legislation could pass before the end of the 110th Congress.  “It’s certainly doable,” he said.